- Home
- TOVX vs OLMA Comparison
TOVX vs OLMA Comparison
Compare TOVX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- OLMA
- Stock Information
- Founded
- TOVX 2001
- OLMA 2006
- Country
- TOVX United States
- OLMA United States
- Employees
- TOVX N/A
- OLMA N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- OLMA Health Care
- Exchange
- TOVX Nasdaq
- OLMA Nasdaq
- Market Cap
- TOVX 3.5M
- OLMA 465.4M
- IPO Year
- TOVX 2006
- OLMA 2020
- Fundamental
- Price
- TOVX $1.14
- OLMA $6.10
- Analyst Decision
- TOVX Strong Buy
- OLMA Strong Buy
- Analyst Count
- TOVX 1
- OLMA 5
- Target Price
- TOVX $6.00
- OLMA $26.25
- AVG Volume (30 Days)
- TOVX 96.3K
- OLMA 1.1M
- Earning Date
- TOVX 11-12-2024
- OLMA 11-12-2024
- Dividend Yield
- TOVX N/A
- OLMA N/A
- EPS Growth
- TOVX N/A
- OLMA N/A
- EPS
- TOVX N/A
- OLMA N/A
- Revenue
- TOVX N/A
- OLMA N/A
- Revenue This Year
- TOVX N/A
- OLMA N/A
- Revenue Next Year
- TOVX N/A
- OLMA N/A
- P/E Ratio
- TOVX N/A
- OLMA N/A
- Revenue Growth
- TOVX N/A
- OLMA N/A
- 52 Week Low
- TOVX $1.14
- OLMA $5.56
- 52 Week High
- TOVX $17.00
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- TOVX 36.15
- OLMA 27.05
- Support Level
- TOVX $1.23
- OLMA $5.56
- Resistance Level
- TOVX $1.21
- OLMA $6.87
- Average True Range (ATR)
- TOVX 0.07
- OLMA 0.81
- MACD
- TOVX 0.01
- OLMA -0.28
- Stochastic Oscillator
- TOVX 0.00
- OLMA 10.12
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.